SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

City Therapeutics, Clinical-Stage RNAi Therapeutics Developer, Files for Nasdaq Global Market IPO

City Therapeutics, a clinical-stage biotechnology company developing RNA interference (RNAi) medicines, filed an S-1 to go public on the Nasdaq Global Market under the ticker CTY. The IPO is led by Goldman Sachs, Jefferies, Stifel and Oppenheimer. Proceeds will fund clinical trials for its lead pro…

Related stories